Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?

Impact · against what's priced in

Apellis Pharmaceuticals is effectively a merger arbitrage play following Biogen's $5.6 billion acquisition offer at $41 per share. Biogen's price reflects the strategic addition of revenue-generating assets and expected EPS accretion, while Autolus sees indirect positive momentum from sector valuation lifts.

APLS+1.00

No priced-in read yet